TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Versus Multi-port Robotic Assisted Sacrocolpopexy for Repair of Vaginal Apex Prolapse
Brief Summary: A prospective randomized controlled study intended to compare the efficacy of 2 methods of robotic assisted sacrocolpopexy for the repair of vaginal apex prolapse:

1. Via single-port.
2. Via multi-port.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: robotic laparoscopic sacrocolpopexy | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Sacral Colpopexy | Intervention Type: PROCEDURE; Name: robotic laparoscopic sacrocolpopexy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Laparoscopic Sacral Colpopexy; Assigned to Arm(s): 1
B: Arm Label: Single-port sacrocolpopexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-port sacrocolpopexy | Arm Label: Multi-port sacrocolpopexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Multi-port sacrocolpopexy | Intervention Type: PROCEDURE; Name: Single-port sacrocolpopexy; Assigned to Arm(s): Single-port sacrocolpopexy | Intervention Type: PROCEDURE; Name: Multi-port sacrocolpopexy; Assigned to Arm(s): Multi-port sacrocolpopexy
C: Arm Label: SSLF and PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF, Behavioral: PMT | Arm Label: ULS and PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS, Behavioral: PMT | Arm Label: SSLF without PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: ULS without PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF and PMT, SSLF without PMT | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS and PMT, ULS without PMT | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): SSLF and PMT, ULS and PMT
D: Arm Label: Hysteropexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Uphold® LITE | Arm Label: Hysterectomy and USLS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Uterosacral ligament suspension | Intervention Type: PROCEDURE; Name: Uterosacral ligament suspension; Assigned to Arm(s): Hysterectomy and USLS | Intervention Type: PROCEDURE; Name: Uphold® LITE; Assigned to Arm(s): Hysteropexy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT-HF)
Brief Summary: CONNECT-HF is a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics.


Options:
A: Arm Label: Direct & Digital; Type: OTHER; Interventions: Other: Digital Engagement, Other: Direct Engagement | Arm Label: Direct & Registry; Type: OTHER; Interventions: Other: Direct Engagement | Arm Label: Digital & Registry; Type: OTHER; Interventions: Other: Digital Engagement | Arm Label: Registry; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Digital Engagement; Assigned to Arm(s): Digital & Registry, Direct & Digital | Intervention Type: OTHER; Name: Direct Engagement; Assigned to Arm(s): Direct & Digital, Direct & Registry
B: Arm Label: Community-eùbedded reproductive health interventions; Type: EXPERIMENTAL; Interventions: Behavioral: Theory of planned behaviour (TPB) and social cognitive theory (SCT). | Arm Label: Community members without intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Theory of planned behaviour (TPB) and social cognitive theory (SCT).; Assigned to Arm(s): Community-eùbedded reproductive health interventions
C: Arm Label: Usual Well-Child Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Redesigned Well-Child Care; Type: EXPERIMENTAL; Interventions: Other: Redesigned Well-Child Care | Intervention Type: OTHER; Name: Redesigned Well-Child Care; Assigned to Arm(s): Redesigned Well-Child Care
D: Arm Label: Early implementation practices; Type: ACTIVE_COMPARATOR; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Arm Label: Delayed implementation practices; Type: OTHER; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Intervention Type: OTHER; Name: Implementation of the MOHR assessment in primary care workflow; Assigned to Arm(s): Delayed implementation practices, Early implementation practices

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of a Low Protein Content Formula Fed to Full Term Healthy Infants in the First Months of Life: a Randomized Controlled Trial
Brief Summary: This study aimed to evaluate the tolerance and safety of a low-protein formula in healthy full-term infants by investigating effects on growth and gastrointestinal tolerance and by identifying any adverse effects.


Options:
A: Arm Label: Formula regimen 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Formula regimen 1 | Arm Label: Formula regimen 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Formula regimen 2 | Arm Label: Reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Formula regimen 1; Assigned to Arm(s): Formula regimen 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Formula regimen 2; Assigned to Arm(s): Formula regimen 2
B: Arm Label: Human Milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Human Milk | Arm Label: Milk based standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Milk based standard infant formula | Arm Label: Milk based investigational infant formula; Type: EXPERIMENTAL; Interventions: Other: Investigational infant formula | Intervention Type: OTHER; Name: Human Milk; Assigned to Arm(s): Human Milk | Intervention Type: OTHER; Name: Investigational infant formula; Assigned to Arm(s): Milk based investigational infant formula | Intervention Type: OTHER; Name: Milk based standard infant formula; Assigned to Arm(s): Milk based standard infant formula
C: Arm Label: Low protein formula group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low protein formula | Arm Label: Standard protein formula group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard protein formula | Arm Label: Breastfeeding group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Low protein formula; Assigned to Arm(s): Low protein formula group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard protein formula; Assigned to Arm(s): Standard protein formula group
D: Arm Label: Protein formula; Type: EXPERIMENTAL; Interventions: Other: Alternate protein infant formula | Arm Label: Standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard infant formula | Intervention Type: OTHER; Name: Alternate protein infant formula; Assigned to Arm(s): Protein formula | Intervention Type: OTHER; Name: Standard infant formula; Assigned to Arm(s): Standard infant formula

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Brief Summary: The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction


Options:
A: Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Anagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: Anagliptin; Assigned to Arm(s): Anagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
C: Arm Label: Sotagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Sotagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sotagliflozin; Assigned to Arm(s): Sotagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Brief Summary: The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.


Options:
A: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg
B: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Canagliflozin (JNJ-28431754); Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, 100 mg, Drug: Canagliflozin, 300 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin, 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) | Intervention Type: DRUG; Name: Canagliflozin, 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ideal Sedation for Stroke Thrombectomy
Brief Summary: The Ideal Sedation for Stroke Thrombectomy (ISST) registry will answer the key questions whether sedation with intubation and paralytics is feasible and whether it delays the time to recanalization in comparison with conscious sedation alone. As a pilot registry, it is anticipated to enroll 40 acute stroke patients requiring mechanical thrombectomy over 12-18 months. Following enrollment, data will be collected prospectively from medical records and from patients' visits.


Options:
A: Arm Label: General Anesthesia; Type: EXPERIMENTAL; Interventions: Drug: General Anesthesia | Arm Label: Conscious Sedation with Remifentanil; Type: EXPERIMENTAL; Interventions: Drug: Conscious Sedation with Remifentanil | Intervention Type: DRUG; Name: General Anesthesia; Assigned to Arm(s): General Anesthesia | Intervention Type: DRUG; Name: Conscious Sedation with Remifentanil; Assigned to Arm(s): Conscious Sedation with Remifentanil
B: Arm Label: General anaesthesia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: General anaesthesia | Arm Label: Conscious Sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conscious Sedation | Intervention Type: PROCEDURE; Name: General anaesthesia; Assigned to Arm(s): General anaesthesia | Intervention Type: PROCEDURE; Name: Conscious Sedation; Assigned to Arm(s): Conscious Sedation
C: Arm Label: Conscious Sedation/Monitored Anesthesia Care; Type: N/A; Interventions: N/A | Arm Label: General Anesthesia; Type: N/A; Interventions: N/A
D: Arm Label: General Anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Local Anesthesia; Type: EXPERIMENTAL; Interventions: Procedure: Local anesthesia | Intervention Type: PROCEDURE; Name: Local anesthesia; Assigned to Arm(s): Local Anesthesia

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Low-dose Aspirin on Fetal Weight of Idiopathic Asymmetrically Intrauterine Growth Restricted Fetuses With Abnormal Umbilical Doppler Indices
Brief Summary: Intrauterine growth restriction refers to a fetus that has failed to get a specific measures by a gestational age. Asymmetric type of Intrauterine growth restriction is known by normal sized head with smaller abdomen.It is important to recognize the growth restricted fetuses, because these fetuses may have fetal or neonatal complications.

When blood flow is increased, the oxygen and nutrients will deliver good to the fetus. The role of low-dose aspirin therapy in management of intrauterine growth restriction is controversial. It has been used, in many studies, in prevention of intrauterine growth restriction especially in women at high risk of pre-eclampsia or obstetrical antiphospholipid syndrome.


Options:
A: Arm Label: Aspirin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin group
B: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Non-intervention group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Low-dose aspirin in women with high risk of preeclampsia | Intervention Type: OTHER; Name: Low-dose aspirin in women with high risk of preeclampsia; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
Brief Summary: The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.


Options:
A: Arm Label: Ketamine, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ketamine, Drug: Placebo | Arm Label: Placebo, Then Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine, Drug: Placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine, Then Placebo, Placebo, Then Ketamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ketamine, Then Placebo, Placebo, Then Ketamine
B: Arm Label: Esketamine + Standard of care; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Other: Standard of Care | Arm Label: Placebo + Standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of Care | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine + Standard of care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Standard of care | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Esketamine + Standard of care, Placebo + Standard of care
C: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Ketamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam
D: Arm Label: Esketamine + Standard of care; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Other: Standard of Care | Arm Label: Placebo + Standard of care; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Other: Standard of Care | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine + Standard of care | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Standard of care | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Esketamine + Standard of care, Placebo + Standard of care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Electronic Cigarette Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers
Brief Summary: Electronic cigarette is proposed as a bridge to smoking cessation. In this study we examine its effects on aortic elasticity, glycocalyx integrity, and exhaled carbon monoxide (CO) concentration and platelet function, both acutely and after 1 month of use.


Options:
A: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: Electronic cigarette with or without nicotine; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic cigarette | Arm Label: Smoker control; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional cigarette | Intervention Type: OTHER; Name: Electronic cigarette; Assigned to Arm(s): Electronic cigarette with or without nicotine | Intervention Type: OTHER; Name: Conventional cigarette; Assigned to Arm(s): Smoker control
D: Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Electronic Cigarette Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers
Brief Summary: Electronic cigarette is proposed as a bridge to smoking cessation. In this study we examine its effects on aortic elasticity, glycocalyx integrity, and exhaled carbon monoxide (CO) concentration and platelet function, both acutely and after 1 month of use.


Options:
A: Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling
B: Arm Label: Electronic cigarette with or without nicotine; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic cigarette | Arm Label: Smoker control; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional cigarette | Intervention Type: OTHER; Name: Electronic cigarette; Assigned to Arm(s): Electronic cigarette with or without nicotine | Intervention Type: OTHER; Name: Conventional cigarette; Assigned to Arm(s): Smoker control
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo

Answer: B